RE:RE:Further clarity needed & size of mkt.My take from the 'vagueness' regarding next steps is that they will be announcing some sort of partnership soon.
Otherwise, they would have stated - idle until we find someone to partner with - continue ourselves with the remianing Phase 1 - issue shares for a phase II - talk to the FDA to validate next steps as to forego last part of P1 and move to P2 in ovarian cancer.
Let's not forget that the goal of the study was safety. So the positive responses they got, in addition to what they've presented last year - is a big bonus. This thing actually works.
My take is that they have a partner canned and are ironing the details in order to annonce something early January. This will be a major catalyst and should take the shareprice above and beyond 250 M$ market cap.
Regarding egrifts, once FDA clears new batch, we're moving up and up. The worst will be behind us.
But no more 'gimme' for these guys.